A M M Eggermont1, F Brunstein, D Grünhagen, T L M ten Hagen. Show Affiliations » 1. Department of Surgical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Abstract
Mesh： See more » AdultAge FactorsAntineoplastic Combined Chemotherapy Protocols/administration & dosageAntineoplastic Combined Chemotherapy Protocols/therapeutic useChemotherapy, Cancer, Regional Perfusion/methodsDoxorubicin/administration & dosageExtremitiesHumansMelanoma/drug therapyMelanoma/pathologyMelphalan/administration & dosageMiddle AgedPatient SelectionSalvage TherapySarcoma/drug therapySarcoma/pathologySkin Neoplasms/drug therapySkin Neoplasms/pathologyTumor Necrosis Factor-alpha/administration & dosage
Substances： See more » Tumor Necrosis Factor-alphaDoxorubicinMelphalan
Year: 2004 PMID： 15477292 DOI： 10.1093/annonc/mdh913
Source DB: PubMed Journal: Ann Oncol ISSN： 0923-7534 Impact factor: 32.976